IND Application Cleared for VOR33 in CD33+ Acute Myeloid Leukemia

The FDA cleared Vor Biopharma’s IND application for its hematopoietic cell therapy VOR33. This decision allows the company to initiate a phase I/IIa clinical trial evaluating tolerability and feasibility of VOR33 in patients with CD33-positive acute myeloid leukemia (AML) who are at high risk of relapse.

VOR33 consists of hematopoietic cells engineered to lack the CD33 protein. Following treatment with VOR33, patients will be eligible to receive the FDA-approved CD33-directed antibody drug conjugate gemtuzumab ozogamicin to prolong leukemia-free survival and determine if VOR33 protects against the myelosuppression that typically accompanies treatment with gemtuzumab ozogamicin.

Source: Vor Biopharma press release, January 14, 2021.